Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases.
Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia, and Australia.
In 2025, revenue amounted to SEK 28 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm.
Sobi Capital Markets Day 2026
Sobi hosted a Capital Markets Day on 18 February 2026.
Q4 and FY 2025 report
Sobi published its Q4 and FY 2025 report on 5 February 2026.
Loading...
Press releases
Upcoming events
Loading...